BioPorto’s NGAL Forms patent is upheld after EPO ruling

Hellerup, DENMARK

Today, the European Patent Office (EPO) has ruled in the opposition case againts BioPorto’s BioPorto's NGAL Forms patent no. EP 2215481. The EPO ruled the patent valid on the grounds that the patent meets the requirements of novelty, inventive step and sufficient description

BioPorto’s European NGAL patent portfolio comprises, besides the above mentioned patent, BioPorto’s issued NGAL ratio patent, NGAL exclusion patent (currently under opposition), NGAL trauma patent and BioPorto’s NGAL cutoff application. Please see BioPorto’s Annual Report for a description of BioPorto’s issued patents, applications and oppositions. The decision is a first instance decision and can be appealed by the opponent. The patent will be valid in case of an appeal.

Peter Mørch Eriksen, CEO of BioPorto, comments: "The outcome was expected as EPO’s initial assessment of the case was fully in BioPorto’s favor. We are very pleased with the outcome."

Further details from:

Peter Mørch Eriksen, CEO

Phone 45 29 00 00, mail

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.


12 announcement 2016 05 18.pdf